With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
|Articles|March 19, 2007
Medicare Part D boosts Rx market in 2006
U.S. prescription sales grew by 8.3%, to $274.9 billion, from 2005 to 2006.
Advertisement
According to IMS Health, measured by dollars, U.S. prescription sales grew by 8.3%, to $274.9 billion, from 2005 to 2006. Measured by number of prescriptions dispensed, the growth rate was 4.6% versus 3.2% in 2005. The market research firm attributes the growth in both dollars and units to several factors, including the implementation of Medicare Part D, increased use of generics in new drug classes, and the availability of new treatments for cancer and diabetes. Looking ahead, IMS predicts that four to seven product launches in 2007 have blockbuster potential and generics will take an even greater toll on brands.
Advertisement
Related to this article
Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.
Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
2
Harms of Public Health Measures Overlooked in COVID-19 Policy Reviews
3
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
4
Trutakna Reduces Proteinuria in Adults With Primary IgAN
5